Omega Funds leads $35M Se­ries A to fu­el At­ten­u­a's cough pro­gram, set for proof-of-con­cept this year

As At­ten­ua con­tin­ues to de­vel­op its lead pro­gram for chron­ic cough, it will be do­ing so with $35 mil­lion in the bank and un­der the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA